FRONTIER BIOTECHNOLOGIES Inc.

Product

Long-acting peptide drug discovery and development platform
HOME>Product
3BNC117 is a novel broad-spectrum HIV neutralizing antibody targeting HIV-1 gp120 CD4 binding site. This fully human mAb is one of the best broad-spectrum neutralizing antibodies for HIV and at the most advanced clinical development stage in the world. Several phase 1 and phase 2 clinical trials have been conducted in the US. It has been shown by non-clinical and clinical studies that 3BNC117 is well tolerated, and it not only blocks viral replication like other AIDS drugs, but also induces immune response to HIV and HIV-infected cells.
3BNC117
Product overview

Develop innovative therapies to better human lives